Prior authorization required with supporting documentation

Prior authorization is required. Submission must include documentation demonstrating the member's diagnosis, the prescriber specialty or consultation, documentation of required prior therapy failures, and that recommended dosing does not exceed the indication‑specific limits listed in the policy.

• Diagnosis and supporting clinical notes (office chart notes, labs, etc.)
• Prescriber is the required specialist or consultation documentation (e.g., dermatologist, allergist, pulmonologist, ENT, gastroenterologist, oncologist as applicable)
• Evidence of required prior therapy failures per indication
• Dosing information showing dose is within the policy's age/weight-specific limits

Indication‑specific prior authorization requirements

The prior authorization must demonstrate that the request meets the indication‑specific criteria (including continuity-of-care or prior approval status), show evidence of positive response for continuation requests where applicable, confirm absence of concurrent biologic or JAK therapy, and adhere to the policy's dosing limits.

• Specify treated indication on the PA submission
• Provide continuity‑of‑care or prior approval documentation if applicable
• For continuation: provide objective evidence of positive response (examples in each indication)
• Confirm patient is not on another biologic immunomodulator or a JAK inhibitor
• If pediatric, include weight-based dosing details

No prior authorization specified in topical listing excerpt

The provided topical and product listing excerpts do not state any prior authorization requirements for dupilumab or the listed topical agents in these sections.

• Topical corticosteroid listings in these chunks are informational; no PA steps are specified

Medium‑potency topical corticosteroids listed; dosing noted

Sections enumerate medium‑potency topical corticosteroids and provide application frequency (typically 'Apply topically to the affected area(s) BID'), but do not state prior authorization requirements for these agents in the excerpt.

• Examples include clocortolone pivalate 0.1% cream, mometasone 0.1% (Elocon), triamcinolone acetonide formulations
• Dosing instruction repeated as 'Apply topically to the affected area(s) BID' in multiple chunks

No PA codes or explicit requirements in this excerpt

No specific prior authorization billing codes or explicit PA process steps are present in the topical product excerpts provided.

• Chunks list product names, formulations, and dosing phrases but do not include PA codes or instructions

Topical listing without PA instructions

This section lists topical agents and application instructions without specifying prior authorization requirements.

• Repeated medium‑potency topical corticosteroid entries with 'Apply topically to the affected area(s) BID' but no PA guidance

Topical product listing only; no PA stated

The excerpt contains only topical agent listings (product names and dosing phrases) and does not indicate prior authorization requirements for those products.

• Examples: clocortolone pivalate 0.1% cream, desoximetasone, fluocinolone acetonide; dosing frequency noted as BID

Medium‑potency topical corticosteroid list with BID dosing

Medium‑potency topical corticosteroids are repeatedly listed with application frequency (BID) and product examples; these chunks do not include prior authorization code requirements.

• Product examples include mometasone 0.1% (Elocon), hydrocortisone valerate 0.2%, triamcinolone acetonide
• Dosing phrase 'Apply topically to the affected area(s) BID' repeated

Topical agents and BID application noted; no PA criteria

Lists topical agents and typical application frequency (BID); the excerpt does not state prior authorization criteria for these topical products.

• Includes multiple formulations (cream, ointment, lotion, gel, spray) and repeated BID instruction

Dose limits and dosing regimen may trigger PA review

References to 'Dose Limit/Maximum Dose' and 'Dosing Regimen' appear in the formulary/therapeutic alternatives tables, indicating that prior authorization review may consider documented dosing and maximum dose adherence when evaluating requests.

• Therapeutic alternatives list dose limits for systemic and inhaled agents (e.g., cyclosporine max 300 mg/day; methotrexate max 25 mg/week)
• PA reviewers may check that requested dupilumab dosing does not exceed the policy's indication‑specific dose limits

Comparative therapies and dosing listed (no explicit PA triggers)

The document lists multiple alternative topical, systemic, inhaled, and intranasal therapies with dosing and maximum dose information for use as comparators; these entries do not themselves establish explicit prior authorization triggers for dupilumab.

• Includes dosing regimens and dose limits for agents used as therapeutic alternatives or comparators
• No explicit PA trigger language is present in these comparator listings

PA must state indication and include pediatric weight‑based dosing

Prior authorization requests must specify the treated indication and, for pediatric patients, provide weight‑based dosing details consistent with the policy's dosing tables.

• Provide indication being treated on the PA
• Include pediatric weight and dosing calculations where applicable
• Reference the policy's initial and maintenance dose tables for the indicated age/weight band

PA and coding: approval duration and informational codes

Policy revisions extended initial approval duration to 12 months for labeled indications and added new indications (CSU, BP, COPD); coding notes list unclassified drug codes (C9399, J3590) as informational but inclusion of codes does not guarantee coverage.

• Initial approval duration changed to 12 months for maintenance therapy
• New indications added include CSU, bullous pemphigoid, and COPD
• Coding references C9399 and J3590 are informational only

Required documentation of prior therapy failures

For multiple indications the policy requires documentation of prior therapy failure (for example, topical corticosteroids and non‑steroidal topical therapy for atopic dermatitis; intranasal corticosteroid for CRSwNP; PPI or corticosteroid for EoE).

• Atopic dermatitis: failure of one medium‑to‑very‑high potency topical corticosteroid ≥2 weeks and one non‑steroidal topical therapy ≥4 weeks
• CRSwNP: failure of maintenance intranasal corticosteroid ≥4 weeks unless contraindicated
• EoE: failure of PPI or corticosteroid unless contraindicated

Required prior or concomitant therapy and adherence evidence

For some indications (e.g., asthma, CRSwNP, atopic dermatitis/prurigo nodularis), the policy requires demonstrated adherence to or trial of specified controller or topical therapies prior to approval or for continuation.

• Asthma: adherence to ICS+LABA or LTRA evidenced by PDC ≥ 0.8 for last 6 months
• CRSwNP: demonstrated adherence to an intranasal corticosteroid unless contraindicated
• Atopic dermatitis/PN: documented trials of listed topical corticosteroids or other topical therapies as specified

No explicit step therapy in topical listings

No step therapy rules or required trial sequencing are described in the topical corticosteroid listing chunks; these sections serve as background formulary information and potency groupings.

• Topical steroid names and medium‑potency groupings are listed without an explicit stepwise algorithm
• Application frequency is frequently shown as BID

Topical excerpts do not define step therapy

No step therapy or prerequisite therapy sequencing is specified in the provided topical excerpts; repeated listings indicate product examples rather than an authorization sequence.

• Chunks repeat medium‑potency corticosteroid products and dosing phrases without stepwise requirements

Repeated medium‑potency topical listings; no step therapy

These topical product sections repeat medium‑potency corticosteroid listings (product names and BID instruction) and do not present explicit step therapy rules.

• Repeated entries include desoximetasone, fluocinolone acetonide, flurandrenolide, hydrocortisone valerate, mometasone, triamcinolone

Topical therapy history may be relevant before advanced therapy

Medium‑potency topical corticosteroid history may be relevant as background prior therapy before authorizing advanced therapies like dupilumab, but the excerpt does not define an enforced sequence.

• Multiple topical corticosteroids and dosing regimens are listed as potential prior/concomitant therapies

Enumerated comparator therapies and dosing (no step sequence)

Appendices enumerate topical, systemic, inhaled and intranasal corticosteroids and immunomodulators with dosing regimens and dose limits that are referenced as comparators; these lists do not themselves create explicit step therapy sequences.

• Includes dosing limits for systemic agents (e.g., cyclosporine, methotrexate) and inhaled controller products
• Used as therapeutic alternatives and comparator dosing rather than PA step definitions

Policy aligns dupilumab as adjunct/later‑line per guidelines

Guideline language in the policy positions dupilumab as adjunct or later‑line therapy for asthma and CSU, implying expectation of prior standard therapies before dupilumab is used.

• GINA recommends Dupixent as adjunct for patients ≥6 years with exacerbations despite high‑dose ICS/LABA and eosinophilic biomarkers
• CSU guidelines still prioritize omalizumab and antihistamine strategies in stepwise algorithms

Step therapy adjustments: reduced prior therapy requirements

Initial criteria changes include reduction in required prior topical corticosteroid trials for atopic dermatitis and reduction in required intranasal corticosteroid trials for CRSwNP; providers should follow the updated policy when documenting prior therapy attempts.

• Atopic dermatitis initial criteria changed from requiring 2 topical corticosteroids to 1
• CRSwNP initial criteria changed from requiring 2 intranasal corticosteroids to 1
• Prurigo nodularis diagnostic criteria updated (itch scale language adjusted)

Submit clinical documentation supporting criteria — risk of denial if omitted

Providers must submit supporting documentation (office notes, labs, other clinical information) that the member meets all approval criteria; failure to submit required documentation may result in denial.

• Office chart notes, relevant laboratory results (e.g., eosinophil counts, biopsy reports), and prior therapy records
• For off‑label uses, submit supporting literature or guideline documentation when required

Off‑label use: prescriber must provide supporting evidence

For off‑label requests (such as immunotherapy‑related pruritus), the prescriber must submit supporting evidence that the requested regimen is within FDA maximums or is supported by NCCN/practice guidelines or peer‑reviewed literature.

• Documentation that regimen is within FDA maximum dosing for any approved indication or is supported by NCCN or peer‑reviewed literature
• Evidence that the member has received the medication for at least 30 days when continuation is claimed, if applicable

Document topical agent, formulation, and BID application when used as prior therapy

Documentation should reflect use of the listed topical corticosteroid(s), formulation, and application frequency (the excerpts repeatedly state 'Apply topically to the affected area(s) BID') if relying on topical therapy as prior or concomitant treatment.

• Specify agent name, strength/formulation, and documented duration of use
• Document application frequency (BID) when cited as prior therapy

Provide age‑ and weight‑based dosing documentation for pediatric PAs

Documentation for pediatric patients must support age‑ and weight‑based dosing (e.g., initial loading and maintenance doses for asthma, EoE, and other weight‑based regimens) as required by the policy.

• Include patient weight and show calculation of loading and maintenance doses per policy tables
• Ensure requested dose aligns with the weight band dosing limits in the policy

Denial risk: missing supporting documentation

Failure to submit required supporting documentation (office notes, labs, other clinical information) showing the member meets all approval criteria may result in denial of the request.

• Missing prior therapy documentation, lack of lab or biopsy confirmation, or absent prescriber consultation notes are common reasons for denial

Denial risk for unauthorized/off‑label indications without supporting evidence

Requests for non‑FDA approved indications that are not addressed by the policy require sufficient off‑label documentation per the off‑label use policies (CP.CPA.09 commercial; CP.PMN.53 Medicaid); without it, such requests may be denied.

• Off‑label requests must reference supporting peer‑reviewed literature or NCCN/practice guideline recommendations
• Refer to the appropriate off‑label policy for the member's line of business

Dose‑limit exceedance may trigger denial

References to 'Dose Limit/Maximum Dose' are present; requests exceeding the policy's documented dosing limits may trigger review or denial.

• Examples include systemic agent caps (e.g., cyclosporine max 300 mg/day) and dupilumab indication‑specific dose ceilings (see dosing tables)
• PA should include justification if proposing a dose above policy limits (off‑label evidence required)

Contraindication: known hypersensitivity will trigger denial

Known hypersensitivity to dupilumab or any of its excipients is a contraindication; requests for members with this contraindication would be denied.

• Confirm no documented allergic reaction to Dupixent or its excipients prior to approval

Coding references informational — verify codes before billing

Coding references included in the policy (e.g., C9399, J3590) are informational only; inclusion or exclusion of codes does not guarantee coverage and providers should verify coding guidance prior to claims submission.

• C9399 and J3590 are listed as unclassified drug/biologic codes for informational use
• Providers should reference current professional coding guidance when billing